| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H36F2N2O2 |
| Molecular Weight | 470.5944 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CN(C[C@@H](C)[C@]1(O)C2=CC=CC=C2)C(=O)[C@@H]3CN(C[C@H]3C4=CC=C(F)C=C4F)C(C)(C)C
InChI
InChIKey=WHPJOAUPIZDJNX-AGGGUQDCSA-N
InChI=1S/C28H36F2N2O2/c1-18-14-31(15-19(2)28(18,34)20-9-7-6-8-10-20)26(33)24-17-32(27(3,4)5)16-23(24)22-12-11-21(29)13-25(22)30/h6-13,18-19,23-24,34H,14-17H2,1-5H3/t18-,19+,23-,24+,28-/m0/s1
| Molecular Formula | C28H36F2N2O2 |
| Molecular Weight | 470.5944 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
PF-00446687 is the highly selective, brain-penetrant, melanocortin 4 receptor (MC4R) agonist. PF-00446687 induced partner preferences formation in females prairie voles after a 6-h cohabitation without mating. PF-00446687 had been in phase I clinical trial for the treatment of sexual function disorders.